Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Dm1, Maytansinoid
2. Dm4, Maytansinoid
3. Dmmo Maytansine
4. Dmmo-maytansine
5. Emtansine
6. Maitansine
7. Maytansine
8. Maytansinoid Dm1
9. Maytansinoid Dm4
10. Mertansine
11. N2'-deacetyl-n2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine
12. Ravtansine
13. Soravtansine
1. Dm4
2. 796073-69-3
3. Wob38vs2ni
4. Ravtansine
5. (14s,16s,32s,33s,2r,4s,10e,12e,14r)-86-chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-(4-mercapto-4-methylpentanoyl)-n-methyl-l-alaninate
6. Unii-wob38vs2ni
7. Maytansinoid Dm 4
8. Dm 4
9. Schembl12719514
10. Ex-a3441
11. Zinc161601616
12. Cs-6866
13. Ac-36376
14. Hy-12454
15. Ds-028663
16. D94659
17. Q27292749
18. Maytansine, N2'-deacetyl-n2'-(4-mercapto-4-methyl-1-oxopentyl)
19. [(1s,2r,3s,5s,6s,16e,18e,20r,21s)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2s)-2-[methyl-(4-methyl-4-sulfanylpentanoyl)amino]propanoate
Molecular Weight | 780.4 g/mol |
---|---|
Molecular Formula | C38H54ClN3O10S |
XLogP3 | 3.2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 9 |
Exact Mass | 779.3218438 g/mol |
Monoisotopic Mass | 779.3218438 g/mol |
Topological Polar Surface Area | 158 Ų |
Heavy Atom Count | 53 |
Formal Charge | 0 |
Complexity | 1430 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 2 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antineoplastic Agents, Phytogenic
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)
Tubulin Modulators
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES. (See all compounds classified as Tubulin Modulators.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
ABOUT THIS PAGE
A Maytansinoid DM4 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Maytansinoid DM4, including repackagers and relabelers. The FDA regulates Maytansinoid DM4 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Maytansinoid DM4 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Maytansinoid DM4 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Maytansinoid DM4 supplier is an individual or a company that provides Maytansinoid DM4 active pharmaceutical ingredient (API) or Maytansinoid DM4 finished formulations upon request. The Maytansinoid DM4 suppliers may include Maytansinoid DM4 API manufacturers, exporters, distributors and traders.
click here to find a list of Maytansinoid DM4 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Maytansinoid DM4 DMF (Drug Master File) is a document detailing the whole manufacturing process of Maytansinoid DM4 active pharmaceutical ingredient (API) in detail. Different forms of Maytansinoid DM4 DMFs exist exist since differing nations have different regulations, such as Maytansinoid DM4 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Maytansinoid DM4 DMF submitted to regulatory agencies in the US is known as a USDMF. Maytansinoid DM4 USDMF includes data on Maytansinoid DM4's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Maytansinoid DM4 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Maytansinoid DM4 suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Maytansinoid DM4 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Maytansinoid DM4 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Maytansinoid DM4 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Maytansinoid DM4 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Maytansinoid DM4 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Maytansinoid DM4 suppliers with NDC on PharmaCompass.
Maytansinoid DM4 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Maytansinoid DM4 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Maytansinoid DM4 GMP manufacturer or Maytansinoid DM4 GMP API supplier for your needs.
A Maytansinoid DM4 CoA (Certificate of Analysis) is a formal document that attests to Maytansinoid DM4's compliance with Maytansinoid DM4 specifications and serves as a tool for batch-level quality control.
Maytansinoid DM4 CoA mostly includes findings from lab analyses of a specific batch. For each Maytansinoid DM4 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Maytansinoid DM4 may be tested according to a variety of international standards, such as European Pharmacopoeia (Maytansinoid DM4 EP), Maytansinoid DM4 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Maytansinoid DM4 USP).
LOOKING FOR A SUPPLIER?